Tschismarov R, Van Damme P, Germain C, De Coster I, et al. Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial. Lancet 2023 Mar 16:S0140-6736(23)00048-X. doi: 10.1016/S0140-6736(23)00048.
PMID: 36934733